8-K filing — ONCOLYTICS BIOTECH INC (ONCY)
Filed: 2026-10-14 AccNo: 0001129928-26-000072 Size: 172 KB Item 8.01: Other Events
Stocks · News reference
Oncolytics Biotech Receives FDA Feedback On Design Of Potential Pivotal Part B Expansion Of REO 033, Its Ongoing Randomized Study Evaluating Pelareorep In Metastatic Colorectal Cancer; Company Believes Responses Represent Important Alignment Regarding Proposed Pivotal Study Design
Company received written feedback from the U.S. Food and Drug Administration ("FDA") regarding the design of a potential pivotal Part B expansion of REO 033, the Company’s ongoing randomized study evaluating
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Oncolytics Biotech Anticipates Reporting Final Results From Group 4 Of Its GOBLET Phase 1/2 Trial In Q4 For Pelareorep With Atezolizumab To Treat Squamous Cell Anal Carcinoma; To Receive Payment Under Grant From Pancreatic Cancer Action Network This Quarter
Oncolytics Biotech® Inc. (NASDAQ:ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced an update regarding the status of its GOBLET Phase
Oncolytics Biotech Expands Pelareorep Patent Protection Strategy Through 2044
New method of use patent covering pelareorep as an immunotherapy for cancer has been issued in several countries, with U.S. issuance expected in the near termThree patent applications are pending, including two method
Oncolytics Biotech Publishes Data On Pelareorep Immunotherapy In Proceedings Of The National Academy Of Sciences